Skip to content

The Journal of Headache and Pain

Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache"

The Journal of Headache and Pain Cover Image
Open Access

Clinical experience with triptans

  • Giorgio Zanchin1Email author,
  • Filippo Dainese1,
  • Federico Mainardi1 and
  • Ferdinando Maggioni1
The Journal of Headache and PainOfficial Journal of the Italian Society for the Study of Headaches and the Italian Society of Pain Clinicians2:21

https://doi.org/10.1007/s101940170021

Abstract

Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT1B,1D receptor agonist, was introduced and realized a real breakthrough in therapy; other agents of this class of drugs called triptans have more recently been used. All of them are effective in relieving the symptoms of migraine, but each exhibits pharmacological and/or clinical features that must be considered for the optimal care and management of the patient. We present here a short overview on the main clinical features of the triptans already in use in Italy.

TriptansMigraineClinical useSumatriptan, ZolmitriptanRizatriptan

Notes

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.